Since 2021, the Obesity Action Coalition (OAC) has led a national public awareness campaign against weight bias with a goal ...
Over the last couple of years, pharmaceutical giant Eli Lilly (NYSE: LLY) has made a splash in the red-hot weight loss space.
In a year and a half, Eli Lilly (NYSE: LLY) has roughly doubled in value. It is now the most valuable pharmaceutical company in the world.
In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on shortage list
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities ...
Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.
The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback